TinyGemsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents ENV-105 Interim Efficacy Results at International Cancer Research Conference
Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on addressing drug resistance in cancer, announced that President and Chief Scientific Officer Neil Bhowmick is presenting interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. ENV-105, a first-in-class CD105/BMP signaling inhibitor, is being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and a Phase 2 trial in combination with apalutamide for metastatic castration-resistant prostate cancer ("mCRPC"). An interim analysis of the Phase 2 trial demonstrated a statistically significant improvement…

